Literature DB >> 19268426

Embryonic stem cell markers expression in cancers.

Matthieu Schoenhals1, Alboukadel Kassambara, John De Vos, Dirk Hose, Jérôme Moreaux, Bernard Klein.   

Abstract

The transcription factors Oct4 and Sox2 are highly expressed in embryonic stem (ES) cells. In conjunction with Klf4 and c-Myc, their over-expression can induce pluripotency in both mouse and human somatic cells, indicating that these factors are key regulators of the signaling network necessary for ES cell pluripotency. Self-renewal is a hallmark of stem cells and cancer and stemness programming could play an important role in cancer. Therefore we compared the expression of Oct4, Sox2, Klf4 and c-Myc in 40 human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database. We found significant overexpression of at least 1/4 pluripotency factors Oct4, Sox2, Klf4 or c-Myc in 18 out of the 40 cancer types investigated. Furthermore, within a given tumor category these genes are associated with tumor progression or bad prognosis. A key goal in cancer research is to identify the mechanism by which cancer stem cells arise and self-renew. The overexpression of Oct3/4, Sox2, Klf4 and/or c-Myc could contribute to the pathological self-renewal characteristics of cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268426     DOI: 10.1016/j.bbrc.2009.02.156

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  106 in total

Review 1.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Permanently blocked stem cells derived from breast cancer cell lines.

Authors:  Gangadharan B Sajithlal; Kristi Rothermund; Fang Zhang; David J Dabbs; Jean J Latimer; Stephen G Grant; Edward V Prochownik
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

Review 3.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 4.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

5.  Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug.

Authors:  Chun Sun; Lu Sun; Yan Li; Xiaonan Kang; Shu Zhang; Yinkun Liu
Journal:  Med Oncol       Date:  2013-02-21       Impact factor: 3.064

6.  Wnt signaling regulation of stem-like properties in human lung adenocarcinoma cell lines.

Authors:  Yan Zhang; Xueyan Zhang; Jinsu Huang; Qianggang Dong
Journal:  Med Oncol       Date:  2015-04-04       Impact factor: 3.064

7.  Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.

Authors:  Naing Lin Shan; Joseph Wahler; Hong Jin Lee; Min Ji Bak; Soumyasri Das Gupta; Hubert Maehr; Nanjoo Suh
Journal:  J Steroid Biochem Mol Biol       Date:  2016-12-05       Impact factor: 4.292

8.  Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer.

Authors:  Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal
Journal:  Mol Med       Date:  2016-09-12       Impact factor: 6.354

9.  Krüppel-like factors 4 and 5: unity in diversity.

Authors:  Inderpreet Sur
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

Review 10.  Concise Review: Human Dermis as an Autologous Source of Stem Cells for Tissue Engineering and Regenerative Medicine.

Authors:  Natalia Vapniarsky; Boaz Arzi; Jerry C Hu; Jan A Nolta; Kyriacos A Athanasiou
Journal:  Stem Cells Transl Med       Date:  2015-08-07       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.